Background and Purpose-Protective effects of bone marrow stromal cells (MSCs) on ischemic brain damage have been highlighted. We examined the possibility that deletion of AT 2 receptor could attenuate the cerebroprotective effects of MSC using AT 2 receptor-deficient mice (Agtr2 Ϫ ) and the effect of selective AT 1 receptor blocker. Methods-Wild-type mice (Agtr2 ϩ ) were subjected to 3 hours of focal brain ischemia followed by reperfusion (ischemia-reperfusion injury). Simultaneously, Agtr2 ϩ -MSC, Agtr2 Ϫ -MSC, or saline was injected through the tail vein. Results-Survival rates at 6 days after ischemia-reperfusion injury were as follows: approximately 50% in saline-injected mice, 80% in Agtr2 ϩ -MSC-injected mice, and 20% in Agtr2 Ϫ -MSC-injected mice. Neurological deficit after ischemia-reperfusion injury was improved in Agtr2 ϩ -MSC-injected mice, but not in Agtr2 Ϫ -MSC-injected mice. After 48 hours of ischemia-reperfusion injury, brain infarct size was reduced in Agtr2 ϩ -MSC-injected mice, but not in Agtr2 Ϫ -MSC-injected mice. Moreover, brain edema was significantly ameliorated in Agtr2 ϩ -MSC-treated mice but not in Agtr2
S troke is one of the leading causes of death and qualityof-life impairment due to neurological deficit; however, radical treatment for stroke is limited. Recently, cellular therapy has been focused on as a new therapeutic approach to restore injured neurons in the chronic stage 1 and to protect neurons from ischemic-reperfusion damage in the acute phase of stroke 2 using bone marrow stromal cells (MSCs), neural stem cells, 3 hematopoietic stem cells, 4 and umbilical cord blood. 5 MSCs are characterized by the ability to self-renew in a number of nonhematopoietic tissues and by their multipotentiality for differentiation into various tissues such as fibroblasts, bone, muscle, and cartilage. 6, 7 In addition, MSC can differentiate into cells with some characteristics of neurons and astrocytes after being implanted into the central nervous system in vivo. 8 -11 MSCs can also protect neurons by secretion of growth factors and cytokines into the brain. [11] [12] [13] Subsequently, many previous reports have demonstrated that MSC transplantation improves functional recovery after stroke. 10, 11, 14, 15 However, the detailed mechanism of the neuroprotective function of MSC after stroke is totally unknown.
Recent large clinical trials such as the LIFE 16 and MOSES 17 studies indicated that blockade of the renin-angiotensin system is effective to prevent a first or recurrent stroke beyond blood pressure-lowering. However, the detailed molecular mechanisms of preventing the onset of such pathological conditions are still an enigma. Angiotensin II is the principal vasoactive substance of the renin-angiotensin system, having a variety of physiological actions, including vasoconstriction, aldosterone release, and cell growth. 18 Angiotensin II binds 2 major receptors, the angiotensin II type 1 (AT 1 ) receptor and type 2 (AT 2 ) receptor. Although the majority of angiotensin II actions are mediated through the AT 1 receptor, accumulating evidence has suggested that the AT 2 receptor in general not only opposes the AT 1 receptor, but also has its own effects independent of an interaction with AT 1 receptor signaling. We reported that activation of the AT 2 receptor attenuated brain injury partly due to a reduction of oxidative stress in the ischemic brain and an increase in cerebral blood flow in the penumbral region in mice subjected to middle cerebral artery (MCA) occlusion. 19 Moreover, we demonstrated that AT 2 receptor signaling also enhanced neural differentiation and the repair of damaged DNA by induction of a neural differentiating factor, methyl methanesulfonate-sensitive 2 (MMS2), which is one of the ubiquitin conjugating enzyme variants. 20 Recent studies have also demonstrated the possibility that stimulation of AT 2 receptors may promote cell differentiation and regeneration in neuronal tissue. 18, 21 Li et al reported that AT 2 receptor stimulation supported neuronal survival and neurite outgrowth in response to ischemia-induced neuronal injury. 22 Moreover, Gallo-Payet et al demonstrated that angiotensin II induces neural differentiation and neurite outgrowth through mitogen-activated protein kinase 23 or nitric oxide 24 through AT 2 receptor activation and is involved in cerebellar development. 25 This accumulating evidence indicates that AT 2 receptor signaling acts as a crucial cerebroprotective factor after stroke.
All components of renin-angiotensin system are detected in cultured MSC by reverse transcriptase-polymerase chain reaction and flow cytometry. 26 The bone marrow renin-angiotensin system has been reported to contribute to regulation of hematopoiesis, especially in erythropoiesis. 27 The AT 2 receptor is reported to be widely expressed in the fetalplacental unit, 28 but is observed at low levels in adult tissues and is re-expressed in some pathological conditions, 29 indicating an important role of AT 2 receptor activation in tissue regeneration. However, the roles of the AT 2 receptor in MSC transplantation after stroke have never been investigated. Here, we examined the possibility that stimulation of AT 2 receptor signaling in MSC could contribute to brain protection in a mouse focal brain ischemia-reperfusion model induced by MCA occlusion.
Materials and Methods

Animals
Adult male AT 2 receptor-deficient mice (Agtr2 Ϫ ; based on C57BL/6J strain) and wild-type mice (Agtr2 ϩ ; C57BL/6J) at 10 to 12 weeks old were used in this study. Mice were provided by CLEA; Tokyo, Japan. There was no difference in blood pressure between these mice (Supplemental Figure I , available online at http://stroke.ahajournals.org). The experimental protocol was approved by the Animal Studies Committee of Ehime University.
Middle Cerebral Artery Occlusion and Reperfusion
Focal cerebral ischemia was induced by occlusion of the left middle cerebral artery with a modified intraluminal filament technique as described previously. 30 For reperfusion injury, the nylon filament was removed from the common carotid artery 3 hours after MCA occlusion.
Preparation of Bone Marrow Stromal Cells
Bone marrow cells were isolated from 6 crushed bones (bilateral of tibias, femurs, and iliac bones) in each experiment and placed in polystyrene cell culture dishes (Corning, NY). After 24 hours of incubation, nonadherent cells were removed, and attached cells were incubated for 24 hours with or without a selective AT 1 receptor blocker, valsartan (provided by Novartis Pharma AG) at a dose of 10 Ϫ7 mol/L. MSC (2.0ϫ10 5 cells suspended in 200 L) were injected through the tail vein after diluting in phosphate-buffered saline (200 L) immediately after the reperfusion. Hemodynamic change such as cerebral blood flow and blood pressure were not changed after MSC injection.
Neurological Score
Neurological deficit was evaluated 24 hours after MCA occlusion using the neurological scores developed by Huang et al. 31 
2,3,5-Triphenyltetrasodium Chloride Staining
To evaluate the ischemic area in the brain, the extracted brain was sliced into 7 coronal sections with 1-mm thickness and stained with 2% 2,3,5-triphenyltetrasodium chloride. Ischemic size and volume were determined as the percentage of 2,3,5-triphenyltetrasodium chloride-unstained area in the total area.
Brain Water Content and Electrolytes
Brain water content was measured by the wet/dry weight method as described previously. 32 Brains were weighed wet and then ovendried at 100°C for 24 hours and reweighed. Brain water content (%) was calculated as (wet weightϪdry weight)/wet weightϫ100.
Progenitor Colony Formation Assays
Fresh Agtr2 ϩ and Agtr2 Ϫ whole marrow cells were assessed by in vitro methylcellulose-based colony-forming unit assay (MethoCult; StemCell Technologies Inc, Vancouver, BC, Canada). Cells were plated at a concentration of 2ϫ10 4 cells per plate. After 2 weeks, the colonies were scored using a dissecting microscope at ϫ20 magnification.
Real-Time Reverse Transcriptase-Polymerase Chain Reaction Method
Real-time quantitative reverse-transcription polymerase chain reaction was performed with a SYBR green I kit (MJ Research, Inc, Waltham, Mass). The polymerase chain reaction primers are described in extended "Materials and Methods" of the supplemental file.
Statistical Analysis
All values were expressed as meanϮSEM. Data were analyzed by Kruskal-Wallis H test. If a statistically significant effect was found, Mann-Whitney rank sum test was used. Survival rate was analyzed by log-rank test. A value of PϽ0.05 was considered statistically significant.
Results
Lack of AT 2 receptor in marrow stromal cells failed to improve survival rate and neurological deficit in mice with ischemia-reperfusion injury.
Marrow stromal cells prepared from C57BL/6J mice (Agtr2 ϩ -MSC), angiotensin II type 2 receptor-deficient mice (Agtr2 Ϫ -MSC) or saline as a control was injected through the tail vein immediately after reperfusion. As shown in Figure  1A , saline-injected mice exhibited approximately 50% survival rate after ischemia-reperfusion injury 6 days after MCA occlusion, whereas approximately 80% of mice with Agtr2 ϩ -MSC injection survived after ischemia-reperfusion injury. Interestingly, Agtr2
Ϫ -MSC-injected mice showed a marked Table. In contrast, blood CO 2 level was lower compared with saline or Agtr2 Ϫ -MSC injected mice. On the other hand, glucose levels were not changed in these mice. Mice exhibited neurological deficits after MCA occlusion such as hemiplegia, loss of balance, and no spontaneous motor activity. Neurological deficit was evaluated by neurological score 24 hours after MCA occlusion/reperfusion. Neurological score was improved in Agtr2 ϩ -MSC-treated mice compared with saline-injected mice; however, such improvement was not observed in Agtr2 Ϫ -MSC-injected mice ( Figure 1B) . Moreover, neurological deficit was significant higher in Agtr2 Ϫ -MSC-treated mice than Agtr2 ϩ -MSC-treated mice, indicating that lack of AT 2 receptor signaling in MSC attenuated the effects of MSC treatment to improve survival and motor activity after focal brain ischemia.
Treatment With Marrow Stromal Cells Did Not Induce a Significant Reduction of Ischemic Brain Area or Improvement of Cerebral Blood Flow After Ischemia-Reperfusion Injury
Next we examined the reasons why the survival rate was attenuated in Agtr2 Ϫ -MSC-injected mice. Brain samples were obtained 24 and 48 hours after ischemia-reperfusion injury and stained with 2,3,5-triphenyltetrasodium chloride ( Figure  2A) . In saline-injected control mice, the maximal ischemic area was found in section 4, and was approximately 25% of the total area after 48 hours of ischemia-reperfusion injury. In saline-injected control mice, the ischemic volume was approximately 50 mm 3 in 24 hours and 80 mm 3 in 48 hours ( Figure 2B ). After 48 hours of ischemia-reperfusion injury, treatment with Agtr2 ϩ -MSC showed a significant reduction of ischemic size but not with Agtr2
Ϫ -MSC as shown in Figure  2B compared with that in saline-injected mice. Moreover, we measured cerebral blood flow in the core and peripheral regions of the MCA territory just before and 1, 2, and 3 hours after MCA occlusion and 1 hour and 24 hours after reperfusion (Supplemental Figure II) . After MCA occlusion, cerebral blood flow in both the core and periphery decreased with an approximately 90% reduction of the basal level in the core and a 40% reduction in the periphery. After removing the nylon filament, cerebral blood flow was increased to approximately 50% of the basal level and increased up to 70% in the core and 50% in the periphery. Treatment with Agtr2 ϩ -or Agtr2 Ϫ -MSC after reperfusion had a tendency to improve cerebral blood flow; however, no significant change was obtained until 24 hours after reperfusion. Furthermore, blood-brain barrier damage evaluated by Evans blue injection 24 hours after ischemia-reperfusion injury was not different in each mouse (data not shown).
Lack of AT 2 Receptor in Marrow Stromal Cells Failed to Attenuate Brain Edema With Ischemia-Reperfusion Injury
Because it is reported an increase in the blood-brain barrier permeability to sodium occurred from 12 to 48 hours after MCA occlusion, 33 we next evaluated brain edema in the 48 hours ischemia-reperfusion-injured brain with the wet/dry method. In sham operated mice, water content in the brain was approximately 77%. On the other hand, saline-injected mice exhibited approximately 80% water content in the brain.
Agtr2
ϩ -MSC-injected mice showed significantly attenuated water content compared with that in saline-injected mice. In contrast, treatment with Agtr2 Ϫ -MSC injection did not show a beneficial effect on brain edema (Figure 3) .
Deletion of the AT 2 Receptor Failed to Reduce Inflammatory Cytokine After Reperfusion
Proinflammatory cytokines such as tumor necrosis factor-␣ are related to the development of brain edema. 34 Next, we assessed inflammatory cytokines in the brain after ischemiareperfusion injury. Tumor necrosis factor-␣ and monocyte chemoattractant protein-1 mRNA expression were increased in the ischemic brain. Treatment with Agtr2 ϩ -MSC suppressed the increase in tumor necrosis factor-␣ and monocyte chemoattractant protein-1 mRNA expression ( Figure 4A-B) , but not monocyte chemoattractant protein-1 expression (Figure 4B) . In contrast, treatment with Agtr2 Ϫ -MSC did not attenuate the increase in tumor necrosis factor-␣ and monocyte chemoattractant protein-1 expression in the ischemic area compared with the saline-injected group. Interestingly, tumor necrosis factor-␣ expression in the contralateral hemisphere was significantly increased in Agtr2 Ϫ -MSC-injected mice compared with that in saline-injected mice ( Figure 4A ).
Increase in Methyl Methanesulfonate-Sensitive 2 Expression in Marrow Stromal Cells
Next, we compared cell characteristics between Agtr2 ϩ -and Agtr2 Ϫ marrow cells. There was no difference in morphological characteristics and proliferative activity, which was evaluated by methylcellulose-based colony-forming unit assay of colony-forming unit-macrophages and colony-forming unit-granulocytes and macrophages using whole marrow cells between them (93.8Ϯ8. 2 Figure 5 ).
Effect of Angiotensin II Type 1 Receptor Blocker on Survival Rate After Ischemia-Reperfusion Injury
Finally, we assessed the effect of treatment with an AT 1 receptor blocker, valsartan, on MSC. Interestingly, valsartantreated-Agtr2 ϩ -MSC-transplanted mice exhibited no operative death until 6 days after ischemia-reperfusion injury. Moreover, treatment of Agtr2 Ϫ -MSC with valsartan increased the survival rate up to 80%, similar to that in the Agtr2 ϩ -MSC-transplanted group without valsartan treatment, as shown in Figure 6 . These results suggest that AT 1 receptor blockade and consequent AT 2 receptor stimulation with unbound angiotensin II could contribute to the protective effects of MSC.
Discussion
Therapeutic benefits of MSC after stroke have been highlighted. Our present findings demonstrate the possibility that the AT 2 receptor is an important molecular determinant of MSC-induced cerebroprotection after stroke. Accumulating evidence from recent major clinical trials indicates that blockade of renin-angiotensin system is effective to prevent a first or recurrent stroke, independent of the blood pressurelowering effect. The AT 2 receptor may be stimulated by unbound angiotensin II together with AT 1 receptor blockade during AT 1 receptor blocker treatment. The contribution of endogenous MSC to brain protection after stroke in humans is a matter of debate; however, our findings could provide a new insight that relative stimulation of AT 2 receptor signaling, with blockade of the AT 1 receptor and simultaneous AT 2 receptor stimulation by AT 1 receptor blocker treatment, could have a therapeutic advantage to prevent neurological disorders after stroke.
Although MSC have been reported to have beneficial effects after stroke such as through their plasticity or ability to secrete growth or protective factors, the detailed mechanism is totally unknown. After injection of PKH-stained MSC or MSC obtained from GFP mice through the tail vein after reperfusion, only few fluorescent cells were observed in the brain after ischemia-reperfusion injury (data not shown), indicating that only a very small amount of MSC could stay in the ischemic region. Therefore, it is difficult to consider that injected MSCs in situ could act as cellular repair factors. Accordingly, in the present study, we considered that MSC could act as an indirect neuroprotective factor to regulate the production and secretion of growth factors and/or cytokines rather than as a direct factor by cellular replacement.
In our study, monocyte chemoattractant protein-1 expression tended to be decreased in Agtr2 ϩ -MSC but not in Agtr2 Ϫ -MSC. However, we could not have a statistical significant difference of monocyte chemoattractant protein-1 level between Agtr2 ϩ -and Agtr2 Ϫ -MSC-injected groups. Therefore, we speculated that the marked decrease in survival rate in Agtr2 Ϫ -MSC-injected mice after ischemia-reperfusion injury was at least partly due to an increase in an inflammatory cytokine, tumor necrosis factor-␣. The antiinflammatory effect of MSC has focused attention on them as potential therapeutic agents in disorders of the immune system to achieve effects by transplantation. Endogenous tumor necrosis factor-␣ and matrix metalloproteinase-9 were increased after MCA occlusion in the brain of rodents. 35, 36 Hosomi et al reported that treatment with antitumor necrosis factor-␣ neutralizing antibody reduced brain infarct volume and cerebral edema, which are likely to be mediated by a reduction in matrix metalloproteinase upregulation. 34 Therefore, MSC injection-induced reduction of tumor necrosis factor-␣ may prevent brain edema and mortality of cerebral ischemia. Interestingly, in Agtr2 Ϫ -MSC-injected mice, tumor necrosis factor-␣ expression was induced in the contralateral side of the brain, indicating that Agtr2 Ϫ -MSC injection through the tail vein induced an inflammatory response even in the ipsilateral area as well as having less potential for brain protection than Agtr2 ϩ -MSC injection. Moreover, in an inflammatory microenvironment, MSCs were rejected by the inflammatory response in an investigation of the plasticity and long-term survival of GFP-labeled MSC transplanted into the normal brain. 37 Therefore, an increase in inflammation also inhibited prevention of brain damage by MSC. Further investigation of the time course of ischemic area and brain edema will clarify the mechanisms of this beneficial effect of injected MSC to induce brain protection.
Recently, we reported that AT 2 receptor signaling induces neurite outgrowth through transactivation of MMS2 expression involving the association of AT 2 receptor interacting protein and tyrosine phosphatase, SHP-1. 38 Our recent data also demonstrated that AT 2 receptor signaling-induced MMS2 upregulation stimulated the DNA repair pathway and decreased DNA damage after ultraviolet radiation. 38 After reperfusion, tissues are exposed to oxidative stress, thereby resulting in neural DNA damage. 39 One possibility is that the loss of function in Agtr2 Ϫ -MSC is due to an increase in DNA damage and loss of number after exposure to reperfusion injury, partly due to decreased expression of MMS2. However, it is difficult to count the number of MSCs after their injection through the tail. Therefore, further investigation is necessary to prove this hypothesis.
Treatment with AT 1 receptor blocker, valsartan, cancelled a failure of brain protective effect in Agtr2 Ϫ -MSC-injected mice. Previously, our report demonstrated that deletion of AT 2 receptor increases stroke size after MCA occlusion 19 and valsartan reduced stroke size in wild-type mice. Although the animal model for stroke was different from the previous paper, similar brain protective effect through AT 2 receptor stimulation was observed. In the present study, we also showed that brain-protective effects through angiotensin receptors by not only an AT 2 receptor stimulation, but also a blockade of AT 1 receptor signaling. The correlation between 2 types of angiotensin receptors in MSC has been further investigated in our laboratory.
Taking these findings together, we conclude that stimulation of AT 2 receptor signaling in MSC plays a pivotal role in the contribution of MSC treatment to brain protection after focal brain ischemia-reperfusion injury.
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